Day Two

• Establish GIP receptor antagonism as a foundational cardiometabolic mechanism, exploring effects beyond appetite suppression and the potential for independent improvements across glycaemic control, lipid metabolism and body composition
• Demonstrate how GIPR antagonism can sensitize complementary nutrient-stimulated hormone pathways, examining the rationale for combining AT-7687 with GLP-1 and amylin-based therapies to enhance efficacy without compounding tolerability10.30 DACRA Debate
• Translate human genetics and preclinical combination evidence into an amylin strategy, leveraging data showing synergy between GIPR antagonism and dual amylin/calcitonin receptor agonism in translational models to inform rational nextgeneration combinations

• Compare methods for measuring fat mass, lean mass, visceral and subcutaneous adipose tissue, bone and broader metabolic changes
• Determine which measurements can be aligned from preclinical models through clinical trials to support meaningful comparison
• Establish what evidence would be needed to demonstrate that any body-composition benefit is specific to a molecule, mechanism or receptor profile

Take part in a structured networking debate exploring one of the field’s most important strategic questions: broad dual amylin/calcitonin receptor agonism versus more selective amylin receptor targeting. Compare the scientific rationale, translational evidence and perceived trade-offs behind each approach, challenge assumptions with peers, and build connections with developers working across both sides of the debate.

• Investigating amylin's potential in type 1 diabetes for glycemic control and hypoglycemia reduction
• Examining metabolic benefits for MASH, kidney disease, and cardiovascular outcomes
• Discussing speculative but intriguing indications: addiction, alcohol use disorder, sleep disorders, and Alzheimer's disease

• Assess what is driving investor conviction in amylin, from major pharma prioritisation and billion-dollar partnering activity to growing interest in preclinical assets, and determine whether the field represents the next major investment cycle after GLP-1s
• Define what makes an amylin company or asset investable, examining which differentiators – efficacy, tolerability, receptor profile, oral or long-acting delivery, combination potential and quality of weight loss – are most likely to justify financing and strategic interest as the competitive landscape expands
• Explore how investors should balance opportunity against scientific risk, identifying the clinical and translational milestones needed to de-risk programmes, where there is still whitespace for new entrants, and when partnering, acquisition or continued independent development creates the greatest value

• Identify where amylin may offer a meaningful alternative for patients prioritizing tolerability, gradual weight loss, lower-BMI intervention or a different treatment experience
• Examine its potential use after incretin intolerance, inadequate response, treatment plateau or discontinuation without assuming these groups are already clinically defined
• Determine what evidence clinicians need to distinguish between amylin, incretins and combinations in individual patients
• Develop practical scenarios for initiation, switching, sequencing, add-on treatment and maintenance

• Gain insight into where investor appetite is building across selective agonists, combination approaches, oral molecules, antibodies and long-acting amylin strategies 
• Understand the key financing stages from seed and Series A through clinical development, strategic partnerships and late-stage capital 
• Identify the scientific and clinical milestones investors need to see to de-risk amylin programmes and support the next funding round 
• Learn how to articulate a differentiated value proposition around receptor strategy, efficacy, tolerability, modality, patient positioning and indication expansion to attract investment and strategic partners